Workflow

GenScript's CytoSinct™ Nanobeads purify cells using a column-based separation method.
*These nanobeads are compatible with magnetic columns for cell isolation from GenScript or another provider.

Application

• T cell Isolation with high purity, recovery and viability from PBMC

  The combined enrichment of CD4+ and CD8+ T lymphocytes is a common cell isolation strategy to produce T cell-based therapies like CAR T. GenScript provides both CytoSinct™ CD4 and CD8 nanobeads. The two magnetic beads can be incubated with the staring material like PBMC or leukopak at the same time and processed for T cell isolation in one-step and obtain high-purity and high-recovery target cells without impact on cell viability.

  

  Figure 1.  PBMCs from different donors were treated with CytoSinct™ or competitor CD4 and CD8 magnetic beads and CytoSinct™ manual separator followed by flow cytometry analysis. (A) Representative result of post-isolation using CytoSinct™ products in comparison to the current standard technology. (B) Cell viability before and after isolation using CytoSinct™ Nanobeads, (C) Purity of T-cells after isolation using CytoSinct™ Nanobeads. (D) Recovery of CD4+ and CD8+ T cell after isolation using CytoSinct™ Nanobeads.

• Single-Step αβ T Cell Depletion with CytoSinct™ TCRαβ Nanobeads

  GenScript’s CytoSinct™ TCRαβ Nanobeads feature an innovative one-step protocol that simplifies workflows and overcomes the challenges of traditional methods—such as lengthy procedures, complexity, and high cell loss. Designed for use with allogeneic CAR-T, γδ T, and CAR-NK cell therapy development, this technology efficiently removes αβ T cells while maximizing the recovery of desired cell populations.

  Workflow Comparison: Single-Step vs. Dual-Step TCRαβ cell depletion

  

  Application of αβ T Cell Depletion in allogeneic CAR-T and  γδ T cell therapy production

  

  Figure 2. TCRαβ depletion using CytoSinct™ TCRαβ nanobeads for allogeneic CAR-T and γδ T cell production from various healthy donor PBMC samples and analyzed by flow cytometry. (A) CD3+ cell percentage after TCRαβ depletion maintained below 0.1%; (B) Purity and recovery of target cell population (allogeneic CAR-T or γδ T) in final products.

  Application of αβ T Cell Depletion in CAR-NK cell therapy production

  

  Figure 3. TCRαβ depletion using CytoSinct™ TCRαβ nanobeads for CAR-NK cell production from various healthy donor PBMC samples and analyzed by flow cytometry. (A) CD3+ cell percentage after TCRαβ depletion; (B) CD3-CD56+NK cell purity and recovery after TCRαβ depletion.

• Highly Efficient NK Cell Isolation

  NK cells are usually enriched from PBMC or leukopaks by CD3+ cell removal followed by CD56+ cell enrichment for NK cell or CAR-NK cell therapy production. GenScript CytoSinct™ provides both CD3 and CD56 Nanobeads for highly efficient NK cell enrichment.

  

  Figure 4. NK cell enrichment from various PBMC samples via CD3+ cell depletion followed by CD56+ cell enrichment using CytoSinct™ CD3 and CD56 Nanobeads or the current standard method. Percentage of T cells (A), NKT cells (B), and NK cells (C) before or after isolation were analyzed by flow cytometry, and the NK cell recovery rate of the whole process (D) and the NK cell recovery rate in CD56 enrichment (E) were evaluated.

• CD34+ Cell Enrichment With Enhanced Safety

  CD34 is validated biomarker of human hematopoietic stem and progenitor cells (HSC and HPC). CD34+ cells are widely used in bone marrow transplant and gene-edited stem cell therapies.

  To ensure its safety, the Fc region of the CD34 antibody used in CytoSinct™ CD34 Nanobeads was humanized to reduce heterology and reduce the risk of producing human anti-mouse antibodies (HAMA). It is also and optimized to reduce non-specific binding of Fc region.

  

  Figure 5. CD34+ cells were enriched from the starting material using CytoSinct™ CD34 Nanobeads or the current standard method followed by flow cytometry analysis. High purity and recovery of CD34+ cells were achieved after isolation and highly comparable as using the current standard method. 

• B Cell Isolation
  

  Figure 6.Enrichment or depletion of CD19+ B cells from PBMC samples using CytoSinct™ CD19 Nanobeads followed by flow cytometry analysis. (A) Representative histogram of CD19+ and CD19- cells before isolation; (B-C) Percentage of CD19+ cells in the positive portion and negative portion after isolation.

Resources

CytoSinct™ Cell Isolation and Activation Solution

Free Download

Cell Isolation and Activation Flyer

Free Download

DMF Letter of Authorization (LoA)

Free Download

Quality Documents

Free Download

Strategic Cooperation

On January 11, 2025, Ucello Biotechnology Co., Ltd. announced that its independently developed umbilical cord blood derived allogeneic CD19-targeted CAR-T cell product, UC101, received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA). This is the first FDA IND approval of an umbilical cord blood derived allogeneic CAR T cell therapy program.

GenScript provided the essential raw materials, including Enceed™ T cell Activation Reagent, CytoSinct™ Cell Isolation Nanobeads (GMP) for various targets, and the CytoSinct™ 1000 instrument. The pre-conjugated, nanoparticle mediated cell isolation and activation technology, along with comprehensive global regulatory support provided by GenScript were crucial in achieving this milestone, making CAR-T cell therapy more accessible to broader range of patients.

---

Ucello Biotechnology

On November 14, 2024, Base Therapeutics Co., Ltd. announced that its independently developed, world-first base-edited universal NK cell product, NK510 Cell Injection, received Investigational New Drug (IND) application approval from the U.S. Food and Drug Administration (FDA) for the clinical treatment of advanced solid tumors. On October 22, NK510 Cell Injection received the IND approval form NMPA.

GenScript is proud to have supported the development of this groundbreaking therapy with our CytoSinct™ Cell Isolation Nanobeads (GMP) and CytoSinct™ 1000 instrument. The CytoSinct™ platform has completed FDA DMF activation, underscoring its readiness for clinical applications.

---

Base Therapeutics

Related Products

CytoSinct™ 1000

View more

Enceed™
T Cell Activation

View more

CytoSinct™
Manual Separator

View more

GMP Grade Cell Isolation and Activation

View more